Company Overview - MDxHealth is a commercial-stage precision diagnostics company specializing in molecular information for personalized patient diagnosis and treatment, particularly in urologic cancers and diseases [1] - The company operates with U S headquarters in Irvine, California, and European headquarters in Herstal, Belgium, with additional laboratory operations in Plano, Texas [1] Financial Performance - The company expects Q4 2024 revenue of $24 7 million and full-year 2024 revenue of $90 0 million, representing 28% year-over-year growth for both periods [2] - For 2025, the company issued revenue guidance of $108-110 million, reflecting 20-22% year-over-year growth [3] - The company anticipates achieving adjusted EBITDA profitability in the first half of 2025 [3] Operational Metrics - In Q4 2024, the company billed 11,789 tissue-based units (50% growth) and 12,036 liquid-based units (10% growth) [2] - For the full year 2024, the company billed 41,586 tissue-based units (31% growth) and 45,700 liquid-based units (28% growth) [2] - The company ended 2024 with a cash balance of $46 8 million [2] Growth Strategy - The company attributes its growth to the strength of its sales channel and expanded menu offerings to its urology customer base [4] - Management expresses confidence in sustaining growth through operating discipline, commercial execution, and underlying market growth [4] Reporting Calendar - Key upcoming financial reporting dates include Q1 2025 results on May 14, 2025, and the annual shareholders' meeting on May 29, 2025 [5] - Additional reporting dates are scheduled for Q2 and Q3 2025 results on August 14 and November 12, respectively [5] Financial Reporting Status - The preliminary financial data for 2024 is unaudited and subject to potential material adjustments during the finalization process [9]
MDxHealth Reports Preliminary Fourth Quarter and Full Year 2024 Revenues and Issues 2025 Revenue Guidance